Navigation Links
Transplanted genetically-modified adipose cells offer potential therapy for liver diseases
Date:12/20/2012

Putnam Valley, NY. (Dec. 20, 2012) Using mesenchymal stromal cells derived from adipose (fat) tissues, genetically modified to express a bioluminescent marker, researchers in Italy have tracked cells after transplantation. The cells were followed from their injection into the spleen of mice modeling liver disease, to their characterization as "hepatic precursors," and to their subsequent migration through the spleen before engrafting at regenerating sites in the liver by bioluminescent imaging.

Their study is described in a recent issue of Cell Transplantation (21:9), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/. It adds to the developments in cell transplantation that have the potential to offer an alternative to liver transplantation for patients with liver disease. It also increases the validation of the therapeutic potential for cell transplantation with cells other than hepatic cells,

"Liver transplantation is the major therapeutic option for patients affected by liver disease," said study co-author Dr. Gabriele Toietta of the Ospedale Pediatrico Bambino Gesu in Rome, Italy. "However, scarcity of organs, high costs and lifelong immunosuppressive treatment make the potential for transplanting hepatic precursor cells an attractive alternative. In addition, hepatocytes obtained from organs are generally not suitable for transplantation."

Historically, the isolation and preservation of hepatic cells from non-living liver donors has been a limiting factor impacting on organ transplantation. The advantage of using adipose tissue derived stromal cells (AT-SCs) comes from the great availability of fat cells and the ease of obtaining them. Also, the possibility of manipulating and transplanting autologous (self-donated) cells eliminates the need for lifelong immunosuppression treatments. However, in cases of genetically-caused liver disease, cells would have to be obtained from other donors than the patient (allogenic), and so would still require immunosuppressive therapy.

In this study, the researchers demonstrated that modified and transplanted AT-SCs were capable of migrating through the spleen, engrafting in the liver into regenerating sites, and persisting in the hepatic parenchyma for up to two months. In addition, the researchers were able to track the AT-SCs transplanted in their study.

"To our knowledge, this is the first use of bioluminescence imaging - which involves the detection of photons from cells expressing luciferase enzymes - to monitor an experimental approach of cell therapy using AT-SCs for liver disorders," said the researchers.

The researchers also discovered the activation of a "promoter" that suggested that the transplanted cells had a "commitment towards hepatogenic differentiation in vivo."

"Our data suggests engraftment and repopulation of injured livers by transplanted AT-SCs and we confirmed that AT-SCs differentiate towards hepatogenic-like characteristics both in vitro and in vivo," concluded the researchers. "In addition, we detected the activation of a promoter - normally silent in adult tissues - but can be re-activated during liver regeneration."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Transplanted neural stem cells slows als onset and progression in mouse models
2. Cell Transplantation study investigates fate and function of cells transplanted to the CNS
3. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
4. Stem cells can repair a damaged cornea
5. Scientists produce eye structures from human blood-derived stem cells
6. Study demonstrates cells can acquire new functions through transcriptional regulatory network
7. Epigenetic signatures direct the repair potential of reprogrammed cells
8. Researchers print live cells with a standard inkjet printer
9. Nanopills release drugs directly from the inside of cells
10. Protein jailbreak helps breast cancer cells live
11. Newly found protein helps cells build tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... & Investor Conference 2016, to be held February 8-9, ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, taking ... February 10-11, 2016. James Sapirstein , Chief ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... supplier of Semantic Graph Database technology has been recognized As “ Best in ... Corporate America Magazine. , “At Corporate America, it’s our priority to showcase prominent ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma ... company that applies its innovative TransCon technology to address ... at an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare ... Date:  , Wednesday, February 10, 2016 Time:  , ... www.ascendispharma.com . --> An audio webcast of ...
Breaking Biology Technology: